Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Assets (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Non-Current Assets for 15 consecutive years, with $350.1 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 40.34% year-over-year to $350.1 million; the TTM value through Mar 2026 reached $1.5 billion, down 29.55%, while the annual FY2025 figure was $355.2 million, 49.09% down from the prior year.
  • Non-Current Assets hit $350.1 million in Q1 2026 for Agios Pharmaceuticals, down from $355.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $717.6 million in Q3 2024 and bottomed at $103.3 million in Q4 2023.
  • Average Non-Current Assets over 5 years is $381.0 million, with a median of $359.6 million recorded in 2023.
  • Year-over-year, Non-Current Assets crashed 74.56% in 2023 and then skyrocketed 575.42% in 2024.
  • Agios Pharmaceuticals' Non-Current Assets stood at $405.9 million in 2022, then crashed by 74.56% to $103.3 million in 2023, then surged by 575.42% to $697.6 million in 2024, then plummeted by 49.09% to $355.2 million in 2025, then fell by 1.42% to $350.1 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $350.1 million, $355.2 million, and $352.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.